Dose-ranging study of anagliptin in Japanese patients with type 2 diabetes - A multi-centre, randomized, placebo-controlled, double-blind, parallel-group study

Japanese Pharmacology and Therapeutics

Volumn 40, Issue 11, 2012, Pages 973-984

  Kaku, Kohei ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Anagliptin; Dipeptidyl peptidase 4 inhibitor; GLP 1

Indexed keywords

ANAGLIPTIN; HEMOGLOBIN A1C; PLACEBO;

ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

EID: 84871831323     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Diabetes Control and Complications Trial Research Group. The absence of a glycemic threshold for the development of long-term complications : the perspective of the Diabetes Control and Complications Trial. Diabetes 1996; 45 : 1289-98.
2. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR; U. K. Prospective Diabetes Study Group. Sulfonylurea inadequacy : efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U. K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002; 25 : 330-6. (Pubitemid 41079631)
3. Drucker DJ, Nauck MA. The incretin system : glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368 : 1696-705. (Pubitemid 46048557)
4. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995; 80 : 952-7.
5. Van Gaal LF, Gutkin SW, Nauck MA. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus : glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control? Eur J Endocrinol 2008; 158 : 773-84. (Pubitemid 351837365)
6. Kato N, Oka M, Murase T, Yoshida M, Sakairi M, Yamashita S, et al. Discovery and pharmacological characterization of N-[2-((2-[(2S)-2- cyanopyrrolidin-1-yl]-2-oxoethyl} amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a] pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor. Bioorg Med Chem 2011; 19 : 7221-7.
7. Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Ito H, et al. International clinical harmonization of glycated hemoglobin in Japan : From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Diabetol Int 2012; 3 : 8-10.
8. Medical Science Digest 2010; 36 : 1132-3.
9. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352 (9131) : 837-53.
10. DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality : comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161 : 397-405.